Tirzepatide and prevention of chronic kidney disease

Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors. In recent clinical trials in per...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosch, Catalina, Carriazo, Sol, Soler, María José, Ortiz, Alberto, Fernandez-Fernandez, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
CKJ Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157759/
https://www.ncbi.nlm.nih.gov/pubmed/37151412
http://dx.doi.org/10.1093/ckj/sfac274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157759/
https://www.ncbi.nlm.nih.gov/pubmed/37151412
http://dx.doi.org/10.1093/ckj/sfac274

Ejemplares similares